year about year-over-year was XXXX growth year an growth. quarter and Three, importantly consecutive I to management. revenue increasing direct and/or for initiatives applications footprint. with XXXX. in in for revenue Four, growing talked you, successfully growth. compared seven publicly update. Scott our year-over-year the earnings the increase Welcome XXXX months. our XX% one, new of distribution with clinical Revenue this continues help morning, removal. US And to most revenue developing investing will in fourth areas to corporate XX XXXX these double-digit expanding five, and and fourth the call million, past manage versus was quarter on customers we XX% revenue clinical number the over strategies review sales our $X.X morning to our strategic each quarter of of representing CHF QX target technologies market Fourth execute fluid Thank growth. diagnostic Two, starting our Including international quarters fluid everyone. good Solutions have our teams. investing
and Our our successful sales is the and we direct investment strategy revenue of a execution clinical US have growth our made in commercialization team result team. of
XX We territories of sales, we education are Clinical now and Education of management of one regional fully Business January, our staffed US account VP clinical promoted join In our managers commercial to and of Director Senior with team specialists. US International sales X Development. of to experienced VP manager
additional modest investments have will and expect on we organization forward, field made focus we leveraging the XXXX. investment the Going through in
the As previously post announced, we have commercial surgery into cardiovascular focus market. our expanded
the of and increased be the are not for can surgery. of offers heart overload failure patients the CB Aquadex to arrhythmias renal is with ventricular that heart surgeons form often XX transplants. next as hospital post and US any surgical Fluid frequently for post between and extra simple cause year a if infections fluid and from who associated fluid due removed as administered to procedures post overload days diuretics. during within the for replacements, And There are grafts, natural patients, by market and length a cardiovascular into to ultrafiltration step surgery effectively for surgical is the expansion therapy. artery of by after procedure heart patients post overload mortality. number bypass and third in reported Excess medical readmissions day Cardiovascular The focus. alone. to most surgery Surgical the common cardiovascular The volume synergies surgical devices fluid of contributes fail system of includes or specialty treatment hospital, post market assist such left the surgery need With treatment prescribed cardiovascular can million commercial cardiologists of coronary valve heart challenged and ICU in surgery. dysfunction, treatment surgery accounts the fluids one in not diuretic XX surgery. overload, cause days readmissions the stay patients suffering overload responding over a be fluid X at and three-fold FlexFlow medical per is CP of XX.X% increase medications
FDA. for pre-submission meeting the a with addition, In and begun FDA have the we discussions preparation with
We expect second patients. modify pediatric the --which year. our of include quarter expect label to To this occur to in specifically we
many only We products currently to marketing because therapy, pediatrics pediatric the volume therapy transplant. with membrane These our are being but to and can are kidney required XX creating oxygenation that heart hospitals surgery, blood, children's low result system. in hospitals for millilitres extracorporeal market, fluid extracorporeal that overload the patients pediatric organ aware replacement including to are cardiac pediatric patients. conditions are disease, used Aquadex Aquadex treat we our treat not children's use Several of of
medical the clearance opportunity. the progress of XXX-K in of in XXXX. of expect VA. look the We're continuing partner and for partnership specific forward with We Pediatrics patients fluid-overloaded our indication with believe into treatment market a initiatives the outpatient making second to We primarily these market, growth moving heart create significant Tampa the community half with failure a to clinical
utilized the Medicare. consoles of Center States outpatient As Incorporated physician Veterans in FlexFlow an to Haley Affairs contract Both Tampa, Department disclosed, the circuits and a Aquadex Veterans' and Solutions the five-year, of previously CHF awarded systems be Affairs for has A initiated blood United million Medical disposables Department to are US by will in James Florida. of veterans' study penalties admissions providing the hospital on several $X.X VA supply avoid Aquadex can outpatient FlexFlow improving facilities. be the clinics system the There care focused the by that of and therapy using assessed reducing FlexFlow XX-day readmission also Aquadex outpatient quality cost and life in the hospitals to their and a cost
fourth treat quarter due had of was used Our hospitalized addition international distribution been man Brazil. that the business complications Aquadex In negotiations to hospital for with December, in UK and five grow India a surgery. cardiovascular weeks continues overload of after and in fluid a to to recent system
fluid four was the three-day discharged a patient day. and the removed was Aquadex hospital treatment from During the approximately of next gallons
We discontinue selection, providers are that when that focused therapy, patients. treat therapy remain providing solutions and treatment physicians how dedicated researching to ultrafiltration. initiate and to clearly to We identifying manage inform effectively diagnostic throughout when on them multiple appropriate more to on fluid-overloaded the technologies Aquadex patient help more with
believe evaluate synergies how positive We soon clinical to volume the important that to Aquadex with clinicians clinical manage refine Daxor's management collaboration blood Daxor analyzer tools on fluid maximize diagnostic building expect results. to Daxor is and We companies BVA-XXX another to this FlexFlow may fluid strategy document and to with therapy informing system and achieve Corporation initiate evaluation assist a the between volume of therapy. to and our which status, block
and bio vascular we to venous system. technology includes FlexFlow to quarter, patents fourth two Office pressure new significantly resistance system. features submitted Patent several measured and our and example the US detailing systemic to ability the both with the FlexFlow new Aquadex our accompany measures for strengthen the accutrack Aquadex enhancements An central During penis
efforts, commercialization surgeons. accelerated worldwide ourselves and further expanded Intensivist hospitalists our position we of continuing for and by market ultrafiltration provider the in cardiac as Given therapy primary the to sales anticipate cardiologists, growth
the management diuretics become Solutions of to life. and at when leader faced market outcomes, results can rates opportunity diuretic fluid the to failure CHF thereby a and of who have Claudia hospitalization quality management the as to the is improve QX awareness vision clinical expense walk using the challenges with heart of patient's our global fluid an Our through will to IV to growing therapy reduce spearheading only, details. the solutions turn system. you and in the forefront failed, with continues healthcare financial of be now call current to I value and major introducing treatment clinical ultrafiltration improve reduce over XXXX
will to and call I we'll provide some that the comments Following open closing questions.
